Quest Partners LLC Acquires 36,652 Shares of Catalent, Inc. (NYSE:CTLT)

Quest Partners LLC raised its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 289.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,300 shares of the company's stock after buying an additional 36,652 shares during the period. Quest Partners LLC's holdings in Catalent were worth $2,986,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Gamco Investors INC. ET AL increased its position in Catalent by 403.3% in the 1st quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company's stock valued at $1,428,000 after acquiring an additional 20,273 shares in the last quarter. UniSuper Management Pty Ltd increased its holdings in shares of Catalent by 509.4% in the first quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company's stock valued at $1,028,000 after purchasing an additional 15,217 shares in the last quarter. Swedbank AB bought a new position in Catalent in the 1st quarter worth approximately $1,659,000. New York Life Investment Management LLC lifted its holdings in Catalent by 67.9% during the 2nd quarter. New York Life Investment Management LLC now owns 297,903 shares of the company's stock worth $16,751,000 after buying an additional 120,502 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock worth $24,550,000 after buying an additional 14,373 shares in the last quarter.

Catalent Trading Down 0.5 %

Shares of NYSE:CTLT traded down $0.29 during mid-day trading on Monday, reaching $58.81. The stock had a trading volume of 767,173 shares, compared to its average volume of 2,029,171. The firm has a 50 day simple moving average of $59.84 and a two-hundred day simple moving average of $58.21. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $61.20. The firm has a market cap of $10.67 billion, a PE ratio of -26.15, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the business posted ($0.10) earnings per share. The company's revenue for the quarter was up 4.2% on a year-over-year basis. On average, research analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Activity

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company's stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock worth $305,931 in the last 90 days. Corporate insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

CTLT has been the subject of several research reports. William Blair reissued a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reiterated a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, StockNews.com raised shares of Catalent from a "sell" rating to a "hold" rating in a research note on Thursday. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.